Castle Biosciences (CSTL) COO Oelschlager Sells $178K of Stock

Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, Inc., sold 8,587 shares of the company in a planned transaction on June 16, 2026. The shares were sold at an average price of $20.71, amounting to a total value of about $177,837.

Insider Buying and Selling at Castle Biosciences, Inc.

In addition to Kristen Oelschlager's sale, Castle Biosciences has seen several insider transactions recently. Derek Maetzold, President and CEO, bought 550 shares at $2.39 on June 15, 2026, and sold 4,172 shares at $20.66 on the same day in planned transactions. Earlier, on June 1, 2026, Maetzold purchased another 6,214 shares at no cost.

Other Institutional Activity in Castle Biosciences

Institutional investors have also been active in Castle Biosciences. BlackRock, Inc. reduced its holdings by 122,300 shares, ending with 2,982,946 shares valued at about $73.2 million. RTW Investments, LP increased its position by 643,098 shares, totaling 2,758,335 shares worth approximately $67.7 million. Meanwhile, Principal Financial Group Inc cut its stake by 37,767 shares, holding 1,769,877 shares valued at $43.5 million. Portolan Capital Management, LLC decreased its holdings by 379,180 shares, leaving them with 1,350,283 shares valued at $33.1 million. Vanguard Capital Management LLC added 1,177,522 shares, reaching a total of 1,177,522 shares valued at $28.9 million.

Castle Biosciences, Inc. Stock Down 40.1%

Shares of Castle Biosciences, trading on the NasdaqGM under the ticker CSTL, were priced at $20.25. The company has a market capitalization of $614.2 million and a forward P/E ratio of -21.77, indicating it is not currently profitable. The stock has a 52-week range between $14.59 and $44.28, with a 50-day moving average of $22.01 and a 200-day moving average of $28.72. The company's beta is 1.023, suggesting moderate volatility.

Recent Earnings

Castle Biosciences reported revenue of $339.9 million, but it experienced a revenue decrease of 4.9%. The company posted a net margin of -3.78% and a return on equity of -2.85%, reflecting challenges in profitability. The next earnings report is expected on August 3, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Castle Biosciences. On May 13, 2026, BTIG maintained its 'buy' rating with a $40 price target. Baird also reaffirmed its 'buy' rating on May 7, 2026, with a target of $43. Canaccord Genuity echoed this sentiment on April 20, 2026, with a $40 target. The consensus target price among analysts is $44, based on 8 opinions.

About Castle Biosciences

Castle Biosciences, Inc. is a healthcare company specializing in molecular diagnostics to support the diagnosis and treatment of various cancers, including dermatologic cancers and uveal melanoma. Headquartered in Friendswood, Texas, the company is led by CEO Derek J. Maetzold and employs 942 people. Castle Biosciences offers a range of diagnostic tests, such as DecisionDx-Melanoma and TissueCypher, serving the dermatology and gastroenterology markets.

Bottom Line

Kristen Oelschlager's planned sale of shares is part of the regular insider trading activity at Castle Biosciences. The company continues to see significant institutional interest, with both reductions and additions to holdings by major funds. Despite recent financial challenges, analysts remain optimistic, maintaining 'buy' ratings and setting price targets that suggest potential upside. Investors will be watching the upcoming earnings report for further insights into the company's performance.